Biomed Central Ltd

SHERPA: Unknown

People

  1. Postow
    Postow
  2. Panageas
    Panageas
  3. Shoushtari
    Shoushtari
  4. Wong
    Wong
  5. Adamow
    Adamow
  6. Ariyan
    Ariyan
  7. Budhu
    Budhu
  8. Busam
    Busam
  9. Chawla
    Chawla
  10. Daniyan
    Daniyan

Groups

  1. Department of Medicine (17)
  2. Melanoma and Immunotherapeutics Service (17)
  3. Solid Tumor Oncology Division (17)
  4. Melanoma Disease Management Team (8)
  5. GSK Faculty (6)
  6. Hematologic Malignancies, Division of (5)
  7. Hematology-Oncology Fellows (5)
  8. Biostatistics Service (4)
  9. Epidemiology and Biostatistics (4)
  10. Sloan Kettering Institute Postdocs (4)
Search Within
  1. "Margaret Callahan"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (7)
  3. Guidelines (1)
Groups
  1. Department of Medicine (17)
  2. Melanoma and Immunotherapeutics Service (17)
  3. Solid Tumor Oncology Division (17)
  4. Melanoma Disease Management Team (8)
  5. GSK Faculty (6)
  6. Hematologic Malignancies, Division of (5)

More Groups

People
  1. Margaret Callahan (17)
  2. Jedd Wolchok (6)
  3. Michael Postow (6)
  4. Alexander Shoushtari (3)
  5. Katherine Panageas (3)
  6. Roberta Zappasodi (3)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2022 (3)
  4. 2021 (3)
  5. 2020 (2)
  6. 2018 (1)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (17)

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
    Journal Article

    Ascierto, P. A.; Tang, H.; Dolfi, S.; Nyakas, M.; Marie Svane, I.; Muñoz-Couselo, E.; Grob, J. J.; Gomez-Roca, C. A.; Chiarion-Sileni, V.; Peltola, K.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
    Journal Article

    Callahan, M.; Amin, A.; Kaye, F. J.; Morse, M. A.; Taylor, M. H.; Peltola, K. J.; Sharma, P.; O'Reilly, E. M.; Meadows Shropshire, S.; O'Brien, S.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Uncovering the hidden structure of T cell compositions in peripheral blood after immune checkpoint inhibitor
    Meeting Abstract

    Peng, X.; Lee, J.; Adamow, M.; Maher, C.; Callahan, M.; Panageas, K.; Shen, R.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
    Journal Article

    Sanborn, R. E.; Pishvaian, M. J.; Callahan, M. K.; Weise, A.; Sikic, B. I.; Rahma, O.; Cho, D. C.; Rizvi, N. A.; Sznol, M.; Lutzky, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
    Meeting Abstract

    Naing, A.; Callahan, M.; Costello, B.; Curti, B.; Hall, E.; Hansen, A.; Long, G.; Joshua, A.; Shankles, B.; Ulge, U.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Journal Article

    Chapman, P. B.; Jayaprakasam, V. S.; Panageas, K. S.; Callahan, M.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; Betof Warner, A.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Journal Article

    Beattie, J.; Rizvi, H.; Fuentes, P.; Luo, J.; Schoenfeld, A.; Lin, I. H.; Postow, M.; Callahan, M.; Voss, M. H.; Shah, N. J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Dynamic monitoring of response to immune checkpoint blockade through deep-learning empowered ultra-sensitive liquid biopsy in melanoma
    Meeting Abstract

    Widman, A.; Khamnei, C.; Bass, J.; Liao, W.; Shah, M.; Robine, N.; Wolchok, J.; Callahan, M.; Landau, D.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Defining tumor resistance to PD-1 pathway blockade: Recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
    Guidelines

    Kluger, H. M.; Tawbi, H. A.; Ascierto, M. L.; Bowden, M.; Callahan, M. K.; Cha, E.; Chen, H. X.; Drake, C. G.; Feltquate, D. M.; Ferris, R. L.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save